With ADCs on the rise, drugmakers embrace a new oncology pillar
PharmaVoice
JUNE 6, 2025
The first one approved by the FDA — Mylotarg from Pfizer subsidiary Wyeth for acute leukemia — came to market in 2000. Now, 15 different molecules have been approved by the FDA. At ASCO, one of the most talked-about studies was a late-stage trial in which the treatment outperformed chemotherapy as a first-line drug.
Let's personalize your content